SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Amsilk partners with 21st.BIO
Advanced materials specialist AMSilk GmbH (Neuried, Germany) and biotech production specialst 21st.BIO (Copenhagen) have announced to join forces to...
Gene therapy supplier MIP Discovery closes £7M Series A financing
The £7m Series A financing of British gene therapy vector specialist MIP Discovery Ltd was led by lMercia Ventures.Existing investor Calculus Capital...
New law to speed up clinical trials
The draft Medical Research Act (Medizinforschungsgesetz) presented by Health Minister Karl Lauterbach in Berlin before Easter is the centrepiece of...
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...